Efficacy and safety of istradefylline in moderate to severe Parkinson’s disease: A phase 3, multinational, randomized, double-blind, placebo-controlled trial (i-step study): Abstracts from the World Congress of Neurology (WCN 2017)

S. Isaacson, K. Eggert, R. Kumar, F. Stocchi, A. Mori, E. Ohta, K. Toyama, G. Spence, G. Clark, M. Cantillon

Research output: Contribution to journalMeeting Abstract

Original languageEnglish
Pages (from-to)351-352
Number of pages2
JournalJournal of the Neurological Sciences
Volume381
DOIs
Publication statusPublished - 2017

Cite this

@article{a74dc6e7f7ac45eeb687be25607b3ecc,
title = "Efficacy and safety of istradefylline in moderate to severe Parkinson’s disease: A phase 3, multinational, randomized, double-blind, placebo-controlled trial (i-step study): Abstracts from the World Congress of Neurology (WCN 2017)",
author = "S. Isaacson and K. Eggert and R. Kumar and F. Stocchi and A. Mori and E. Ohta and K. Toyama and G. Spence and G. Clark and M. Cantillon",
year = "2017",
doi = "10.1016/j.jns.2017.08.999",
language = "English",
volume = "381",
pages = "351--352",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",

}

TY - JOUR

T1 - Efficacy and safety of istradefylline in moderate to severe Parkinson’s disease: A phase 3, multinational, randomized, double-blind, placebo-controlled trial (i-step study)

T2 - Abstracts from the World Congress of Neurology (WCN 2017)

AU - Isaacson, S.

AU - Eggert, K.

AU - Kumar, R.

AU - Stocchi, F.

AU - Mori, A.

AU - Ohta, E.

AU - Toyama, K.

AU - Spence, G.

AU - Clark, G.

AU - Cantillon, M.

PY - 2017

Y1 - 2017

U2 - 10.1016/j.jns.2017.08.999

DO - 10.1016/j.jns.2017.08.999

M3 - Meeting Abstract

VL - 381

SP - 351

EP - 352

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

ER -